News
Investor's Business Daily on MSN4d
Is Exact Sciences, Down 8%, 'Throwing Good Money At Bad' In Its New Licensing Deal?Exact Sciences stock crashed Thursday as the Street debated the merits of its licensing deal for a blood-based colon cancer ...
Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm ...
Exact Sciences (NASDAQ:EXAS) said it has secured exclusive rights to both current and future iterations of Freenome’s ...
Exact Sciences Corp. (NYSE:EXAS) on Thursday reported a second-quarter 2025 EPS loss of 1 cent, up from a 9-cent loss a year ...
Brisbane, California Friday, August 8, 2025, 10:00 Hrs [IST] ...
The layoffs come despite CEO Kevin Conroy telling investors the company had just completed an “unbelievable quarter” for the ...
Cathie Wood is one of the country's best known growth investors, but sometimes, she acts like an umbrella-toting value ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...
SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...
Cancer vaccine experts are worried that if the Trump administration takes a hostile posture towards mRNA broadly, cancer ...
Exact Sciences’ gross margin for the quarter was 69%, with adjusted gross margin at 72%. The company reported operating cash flow of $89 million and free cash flow of $47 million, ending the quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback